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Abstract HLA class I presentation of pathogen-derived peptide ligands is essential for CD8+ T-
cell recognition of Toxoplasma gondii infected cells. Currently, little data exist pertaining to
peptides that are presented after T. gondii infection. Herein we purify HLA-A*02:01 complexes
from T. gondii infected cells and characterize the peptide ligands using LCMS. We identify 195 T.
gondii encoded ligands originating from both secreted and cytoplasmic proteins. Surprisingly, T.
gondii ligands are significantly longer than uninfected host ligands, and these longer pathogen-
derived peptides maintain a canonical N-terminal binding core yet exhibit a C-terminal extension of
1–30 amino acids. Structural analysis demonstrates that binding of extended peptides opens the
HLA class I F’ pocket, allowing the C-terminal extension to protrude through one end of the
binding groove. In summary, we demonstrate that unrealized structural flexibility makes MHC class
I receptive to parasite-derived ligands that exhibit unique C-terminal peptide extensions.
DOI: 10.7554/eLife.12556.001
Introduction
CD8 T-cells mediate immunity to Toxoplasma gondii infection (Khan et al., 1988; Suzuki and Rem-
ington, 1988) through recognition of peptide antigens presented by the MHC class I (MHC I) mole-
cules of infected cells (Brown and McLeod, 1990; Deckert-Schlu¨ter et al., 1994). The majority of
peptide ligands identified to date are derived from parasite surface proteins, proteins localized to
dense granules, or the rhoptry proteins which are specialized secretory granules whose contents are
released either into the host cell cytoplasm or the parasitophorous vacuole (Blanchard et al., 2008;
Cardona et al., 2015; Cong et al., 2011). These secreted proteins are thought to be optimal candi-
dates for MHC I presentation because they have the best access to conventional antigen processing
and presentation machinery in the host cell. However, this is a large pathogen, and the full array of
parasite proteins that might be sampled and presented remains unknown.
Recent advances in immunology and proteomics highlight that non-canonical ligands are pre-
sented to T cells by MHC I molecules. While a majority of peptides are 8–11 amino acids in length,
MHC I molecules present a considerable number of peptides >11 amino acids (Hassan et al., 2015;
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Schittenhelm et al., 2014) that elicit T-cell responses (Hassan et al., 2015; Burrows et al., 2006).
Structural characterizations suggest that these long ligands interact with the MHC I molecule much
like canonical peptides: The MHC I alpha chain forms a 10 x 25 angstrom groove in which peptide
ligands are anchored by their second (P2) and C-terminal (PW) residues. In this mode of binding, the
middle portion of any oversized peptides can bulge out of the MHC I groove and interact with the
receptors of T lymphocytes (Tynan et al., 2005). Crystallographic studies have confirmed this bulg-
ing model, although there exists a structural example of a 10mer interacting with MHC I molecule
HLA-A2 via P2 and P9 with an amino acid extension at P10 (Collins et al., 1994). Thus, both peptide
extension and peptide bulging have been observed for MHC I ligands, and, as longer ligands
become increasingly evident, the interaction of these ligands with MHC I will need to be clarified.
The goal of this study was to have the MHC I of infected cells inform the number, breadth, and
nature of T. gondii peptide ligands. HLA-A*02:01 was purified from cells infected with T. gondii and
peptide ligands eluted from the HLA class I (human MHC I) complex were analyzed by two-dimen-
sional LCMS. The resulting data demonstrate that nearly 200 ligands originating from close to 100
different T. gondii proteins are sampled for MHC I presentation. As envisioned, a number of ligands
originating from dense granule proteins was observed (Blanchard et al., 2008; Cong et al., 2011),
yet MHC I ligands were also derived from a large number parasite cytoplasmic proteins. Surprisingly,
T. gondii ligands were significantly longer than existing structural models can accommodate, and a
series of peptide analogs demonstrated that these longer peptides are not anchored to MHC I via
their C-termini. Crystallographic studies reveal an unreported structural re-arrangement of residues
in the MHC I binding groove that accommodate C-terminal peptide extensions, and this structural
flexibility is discussed in the context of infection by intracellular pathogens.
Results
Identification of Toxoplasma gondii HLA-A*02:01 ligands
The first objective of this study was to identify pathogen-encoded ligands made available by MHC I.
To accomplish this objective, HLA-A*02:01 was purified from T. gondii infected THP-1 monocytes as
described. (McMurtrey et al., 2008; Wahl et al., 2009). To ensure THP-1 cells were infected, the
number of infected cells and free parasites were periodically assessed. Over the course of a 1-week
infection, the number of infected cells increased from 12.1% day 1 post infection to 71.5% on day 7
eLife digest Toxoplasma gondii is a parasite that can infect most warm-blooded animals and
cause a disease called toxoplasmosis. In humans, toxoplasmosis generally does not cause any
noticeable symptoms, but it can cause serious problems in pregnant women and individuals with
weakened immune systems.
T. gondii is one of many parasites that hide within human cells in an attempt to avoid detection
by the immune system. However, proteins called Human Leukocyte Antigens, or HLAs, can reveal
hidden parasites by carrying small sections of them from the inside the infected cell to the cell’s
surface. The immune system can then recognize the fragments as foreign and attack the parasite.
HLAs typically pick up parasite fragments of a certain length, which enables the immune system
to recognize that what is being displayed is a piece of parasite. By purifying HLAs from cells that
have been infected by T. gondii, McMurtrey et al. have now learned more about which fragments of
the parasite are displayed to the immune system. This analysis revealed that the parasite somehow
manipulates the HLAs to carry parasite fragments that are considerably longer than can be
explained with our current knowledge of how HLAs work. By using a technique called X-ray
crystallography, McMurtrey et al. also show that the structure of the HLA assumes a previously
unseen configuration when interacting with fragments of T. gondii.
In the future, it will be important to understand how infected cells give rise to unusual structural
configurations of HLAs and to unravel how these structures affect the immune system’s ability to
fight infections.
DOI: 10.7554/eLife.12556.002
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post infection (Figure 1). A steady increase in the number of free parasites in the culture media from
day 1 to 7 was indicative of a productive infection. The production of 12 mg HLA-A*02:01 from
infected cells was sufficient for a comprehensive analysis of T. gondii peptide ligands.
Peptide ligands eluted from HLA complexes were separated by offline HPLC fractionation and
subjected to nanoLCMS. A total of 284 peptide sequences precisely matched the reported sequence
of T. gondii. Strikingly, 89 of these peptides were either an exact match or contained an isobaric Ile/
Leu ambiguity match to sequences of the H. sapiens host species (Supplementary file 1), leaving
Figure 1. Kinetics of the T. gondii infection in the bioreactor production. (A) Raw flow cytometry data and gates of
the samples taken from the bioreactor on each indicated day post infection. (B) Histogram of the percent of
infected cells (black bars) as well as the normalized free parasite counts (blue line). Raw parasite counts were
normalized to the total counts of each respective experiment.
DOI: 10.7554/eLife.12556.003
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195 ligands definitively derived from T. gondii (Supplementary file 2). Of these confirmed T. gondii
derived ligands, most (159) show little (<50%) similarity to H. sapiens while 36 peptides have >50%
similarity. In summary, 31% of the T. gondii derived ligands are identical to H. sapiens sequences,
13% show host similarity, and 56% of the T. gondii ligands have no similarity to host proteins (Fig-
ure 2). MHC I makes hundreds of parasite-encoded ligands available to the immune system.
Source proteins of T. gondii ligands
Previous studies have focused upon dense granule proteins (GRA) that are secreted by T. gondii into
the cytosol of the host cell, and a handful of GRA ligands have been reported (Blanchard et al.,
2008; Cardona et al., 2015; Cong et al., 2011; 2012). In our dataset, the 195 T. gondii ligands
identified originate from 95 different proteins of which 87 are non-GRA proteins, demonstrating that
a considerable number of proteins are accessible to MHC I presentation. For 55.8% of the T. gondii
source proteins a single peptide was presented (Figure 3A), while elongation factor 1 alpha pro-
vided 12 peptide ligands. Peptide ligand enrichment from particular proteins was not due to protein
length as median protein lengths were not statistically different (Kruskal-Wallis test, p = 0.247)
regardless of the number of ligands embedded within a protein (Figure 3—figure supplement 1).
Amongst the proteins sampled more than once, a hierarchy emerged whereby several hypothetical
proteins were most frequently sampled followed by the dense granule proteins, ribosomal proteins,
EF1a, tRNA synthetases, and HSP70, respectively (Figure 3B, Supplementary file 2). All together,
multiply sampled T. gondii source proteins provided 44.2% of the pathogen-derived ligands. Dense
granule proteins have been reported as a source of peptides (Blanchard et al., 2008;
Cardona et al., 2015; Cong et al., 2010; 2011; 2012; El Bissati et al., 2014), and here 30 GRA
ligands (15%) were observed with GRA12 providing the most (Hassan et al., 2015) peptide ligands
(Figure 3C). The secreted GRA proteins represent a minority protein source in the rich ligand land-
scape of this pathogen.
In the search for trends and biases in T. gondii peptide ligands, we tested for significant enrich-
ments in cellular compartments of sampled source proteins. There was a significant enrichment in
proteins localized to the apical part of the T. gondii cell (GO:0045177, p = 1.50 x 10-8) and to the
parasitophorous vacuole (GO:0020003, p = 2.79 x 10-6). Unexpectedly, there was a significant
enrichment in proteins originating from the parasite cytoplasm (GO:0005737, p = 9.31 x 10-4) with
21 of 95 proteins annotated as cytoplasmic. This enrichment in peptides derived from T. gondii cyto-
plasm proteins shows that T. gondii does not sequester cytoplasmic proteins from host MHC I anti-
gen processing and presentation.
Figure 2. Sequence identity of identified T. gondii ligands to H. sapiens. T. gondii derived sequences were BLAST
searched against the NCBInr H. sapiens proteome. Sequence identity was recorded and ligands with <50%
sequence identity were considered not significant and were binned together.
DOI: 10.7554/eLife.12556.004
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T. gondii ligands are enriched from the C-terminal end of the source
protein
A recent study showed that the C-terminal location of an epitope within the source protein was
important for T. gondii ligand presentation and immunodominance (Feliu et al., 2013). Given this
observation, we assessed the location of ligands within their source proteins to determine if a C-ter-
minal bias was maintained. Normalized ligand position was calculated as described by Kim et al.
(Kim et al., 2013) and were binned into 5 positions with the most N-terminal bin being 0–0.2 and
the most C-terminal bin being 0.8–1.0 (Figure 4). When the T. gondii ligands were compared to the
baseline uninfected ligand distribution there was a significant reduction in N-terminal peptides (bins
0–0.2, p = 2.36 x 10-4 and 0.2–0.4, p = 2.23 x 10-4, comparison of proportions) along with significant
Figure 3. Ligand sampling of source proteins. (A) The number of distinct ligands from a given source protein was
counted binned by number of ligands. Gene symbols of the most sampled proteins are shown above the
respective bin. (B) Distribution of ligands by source protein group or individual source protein. (C) Distribution of
ligands by source dense granule protein.
DOI: 10.7554/eLife.12556.005
The following source data and figure supplement are available for figure 3:
Source data 1. PEAKS export file containing HLA-A*02:01 peptide H. sapiens derived ligands from uninfected
THP-1 cells.
DOI: 10.7554/eLife.12556.006
Figure supplement 1. Number of ligands do not correspond to source protein length.
DOI: 10.7554/eLife.12556.007
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enrichment in ligands from the C-terminal end of the protein (bins 0.6–0.8, p = 1.46 x 10-2 and 0.8–
1.0, p = 5.26 x 10-7). There was no significant change (p = 0.238) to the central ligands (bin 0.4–0.6).
Next, host-derived ligands from the infected and uninfected cells were compared to see if the C-ter-
minal bias of pathogen encoded peptides extended to the infected host. There was significant
reduction in the 0.2–0.4 bin (p = 0.007) with a significant increase (p = 0.0095) in the very C-terminal
bin (p = 0.0095). In summary, T. gondii ligands are significantly enriched from the C-terminal end of
their source proteins and host-derived peptide ligands shift towards the C-termini of their respective
source proteins following infection.
T. gondii ligands are significantly longer than host ligands
Our in depth proteomics approach identified thousands of HLA-A*02:01 peptide ligands of a canoni-
cal length of 8–11 as well as ligands of non-canonical length. Noteworthy is that a number of the T.
gondii ligands were much longer than expected for the HLA-A*02:01 molecule (Figure 5). When
compared with the host-derived ligands, the T. gondii ligands were significantly longer (t-test,
Figure 4. Location of ligands within respective source proteins. Normalized ligand location within the respective
source protein from the unambiguous T. gondii ligands (black), H. sapiens ligands from infected THP-1 cells
(white) and, H. sapiens ligands from uninfected THP-1 cells (grey).
DOI: 10.7554/eLife.12556.008
Figure 5. Length distribution of identified ligands. Length distributions of unambiguous T. gondii ligands (red), H.
sapiens ligands from infected THP-1 cells (purple) and, H. sapiens ligands from uninfected THP-1 cells (blue).
DOI: 10.7554/eLife.12556.009
The following source data is available for figure 5:
Source data 1. PEAKS export file containing HLA-A*02:01 peptide T. gondii derived ligands from T. gondii
infected THP-1 cells.
DOI: 10.7554/eLife.12556.010
Source data 2. PEAKS export file containing HLA-A*02:01 peptide H. sapiens derived ligands from T. gondii
infected THP-1 cells.
DOI: 10.7554/eLife.12556.011
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p<0.001) with an average length of 14.6 amino
acids compared with 11.4 amino acids in the
host ligands from the infected cells and with 9.8
for uninfected host ligands. This increase in host
ligand length following infection was statistically
significant (t-test, p<0.001). Thus, infection
increases the length of T. gondii and host-
derived ligands.
T. gondii ligands contain a C-
terminal extension from an N-
terminal binding core
To investigate how long peptides observed fol-
lowing infection might bind to MHC I, in silico
algorithms were used to predict HLA-A*02:01
ligand binding affinity. NetMHCpan 2.8 pre-
dicted that 117 of 195 ligands (60%) bind at a
percentile rank score <=10%, leaving 78 pre-
dicted non-binders (Figure 6). As these long
peptides were purified from the HLA-A*02:01 of
infected cells, we hypothesized that the pre-
dicted non-binders interact with HLA-A*02:01 in
a non-canonical fashion that escapes algorithms
trained on canonical binding data. A subsequent
search revealed nested core sequences of 8–11
amino acids within the longer peptides that
were not predicted to bind, and these cores
were predicted to bind to HLA-A*02:01. Strik-
ingly, a considerable number (52/78) of the pre-
dicted non-binders contained nested core
sequences of 8–11 amino acids that were pre-
dicted to bind with high affinity (percentile rank score <=2%). This was significantly more (p = 1.2 x
10-10, comparison of proportions) than if the sequences were randomly scrambled (13/78). Hence, a
binding core appropriate in length and sequence for interaction with HLA-A*02:01 was embedded
within long T. gondii peptides.
We next assessed the positioning of binding cores within longer ligands. Within the T. gondii
ligands, most (36/52) binding cores were at the very N-terminus with the peptide extending from
the core’s C-terminus (Supplementary file 3). This occurred significantly more than randomly scram-
bled versions of the peptides (1/13) (p = 3.1 x 10-5, comparison of proportions). There was no signifi-
cant increase in proportions of ligands with an N-terminal extension (1/52) or an extension on both
sides (15/52) compared to scrambled ligand sequences (0/13 and 12/13 respectively). Noteworthy
was that 10/15 of the peptides with predicted extensions on both sides of a central core had an
alternate binding core at the N-terminal side with a predicted affinity slightly weaker than the central
binding core (Supplementary file 3). So, most peptides could bind either at the N-terminal end or
in the center, and many of the ligands with central cores possessed an alternate N-terminal core.
Among the N-terminal binders, the average C-terminal extension was 8.7 amino acids and the exten-
sion varied considerably from 1 to 30 amino acids (Supplementary file 3). In summary, most of the
long T. gondii predicted non-binders had an N-terminal binding core with a considerable C-terminal
extension.
The observation of C-terminally extended peptides among the T. gondii derived ligands
prompted a similar analysis of the host ligand repertoire from infected cells. Among ligands from
uninfected cells, 2.3% had a C-terminal extension - the baseline of extended peptides in uninfected
THP-1 cells. After T. gondii infection, the percentage of host ligands with a C-terminal extension sig-
nificantly increased to 7.2% (p<0.0001, comparison of proportions) (Figure 6), a percentage that is
less than half the T. gondii derived ligands with extensions (18.5%). Thus, T. gondii infection results
Figure 6. Binding prediction analysis of eluted ligands.
Percentage of total ligands in indicated dataset that
are predicted to be canonical binders (blue), contain a
C-terminal binding core (red), contain an N-terminal
binding core (green), contain a central binding core
(purple), or not predicted to bind (orange).
DOI: 10.7554/eLife.12556.012
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in C-terminally extended host ligands being nearly 3 times more frequent and T. gondii C-terminally
extended ligands being eight times more common.
Predicted extended T.gondii ligands bind HLA
The observation of nested binding cores at the N-termini of extended ligands suggests a novel inter-
action of T. gondii peptides and MHC I. To confirm that the N-terminal portion of the peptides were
binding to HLA-A*02:01, we synthesized full-length peptides and their corresponding binding cores
and determined their affinities for HLA-A*02:01 in a competitive binding assay. Twelve ligands hav-
ing binding cores with the highest predicted binding affinities (Supplementary file 3, bold) were
selected for testing in this manner. Of these 12 peptides, eight binding cores bound with high affin-
ity (<500 nM), three with moderate affinity (<1000 nM), and one had no affinity – the N-terminal
cores overwhelmingly bound to HLA-A*02:01. Two of the twelve full-length ligands (YLSPIASP-
LLDGKSLR-RPL7A15-30) and FVLELEPEWTVK-UFP16-27) also bound with high affinity (Figure 7A) even
though predictions ranked them as non-binders as their C-termini were incompatible with the HLA-
A*02:01 binding motif. The remaining 10 long peptides did not bind in this in vitro assay, perhaps
because they are incapable of binding in the absence of molecular chaperones or the distinct condi-
tions of the infected cell. These data confirm that the N-termini of extended peptides have a strong
affinity for MHC I.
Next, the two extended peptides that bound in the in vitro binding assay were tested to see if
the binding core of the full-length ligand was essential for binding. In order to assess the contribu-
tion of the putative core for peptide binding, HLA-A*02:01 binding assays were completed using
the full length peptide, the binding core only, and a series of full length peptide variants containing
non-permissive amino acid substitutions at the putative C-terminal anchor of the binding core. For F-
VLELEPEWTVK, the affinity of all ’mutant’ peptides was significantly worse (t-test, p<0.05) than
either the binding core or the native full-length peptide (Figure 7B). With YLSPIASPLLDGKSLR, all
but one (L10E) of the mutants had a lower binding affinity in comparison to the wild type sequence
(t-test, p<0.05) (Figure 7B). As YLSPIASPLLDGKSLR harbors a Leu at P9 and at P10, it could be that
either Leu can serve as an F’ pocket anchor for HLA-A*02:01 and when the P10 was changed to an
acidic residue like L10E, the P9 Leu was used as the F-pocket anchor. In summary, the binding core’s
F-pocket residue is critical for long-peptide binding to HLA-A*02:01 such that C-terminal amino acid
extensions of these longer ligands somehow protrude out of the groove in the vicinity of the F-
pocket.
Thermostability of extended ligand complexes
Extended ligands YLSPIASPLLDGKSLR-RPL7A15-30 and FVLELEPEWTVK-UFP16-27 bound at high affin-
ity to HLA-A*02:01, and we next assessed their relative stability when in complex with MHC I. To
determine the relative stability of these extended peptide/MHC I complexes, we completed a ther-
mal denaturation assay on the extended peptides and their respective binding cores in complex
with HLA-A*02:01 (Figure 8). The melting temperature (Tm) for the two extended ligands exceeded
62˚C (YLSPIASPLLDGKSLR, Tm = 66˚ C, FVLELEPEWTVK Tm = 63˚C), temperatures that are consis-
tent with ligands of conventional length (Hassan et al., 2015). The Tm of these extended ligands are
also within the range of 15 mers that are reported to ’bulge’ in the central portion of HLA-A*02:01
binding groove (Hassan et al., 2015). It was somewhat surprising that these extended ligands had
Tm representative of canonical ligands, and more remarkable was that the thermostability of the
binding cores was at least 10˚C higher (YLSPIASPLLDGKSLR, DTm = 10˚C, FVLELEPEWTVK DTm =
12˚C) than their extended counterparts (Figure 8). Thus, extended ligands have a denaturation tem-
perature consistent with those of conventional ligands, possibly due to the highly thermostable
nature of their binding cores.
The C-terminus of extended ligand FVLELEPEWTVK protrudes through
the binding groove
To determine how C-terminal extensions protrude from the F’ pocket of MHC I, we bound the
extended ligand FVLELEPEWTVK (UFP16-27) and its binding core FVLELEPEWTV (UFP16-26) to HLA-
A*02:01, crystallized these two complexes, and solved their structures at a resolution of 1.5 A˚ and
1.87A˚, respectively (Supplementary file 4). Both peptides bound in a zig-zag fashion in order to
McMurtrey et al. eLife 2016;5:e12556. DOI: 10.7554/eLife.12556 8 of 19
Research article Immunology Microbiology and infectious disease
accommodate the core 11 amino acids in the antigen-binding groove (Figure 9A). The 11 amino
acid core of extended ligand FVLELEPEWTVK interacts with HLA-A*02:01 in an almost identical man-
ner to the shorter peptide, however, both the main chain and side chain of C-terminal Lys12 pro-
trudes out the end of the binding pocket (Figure 9B). Electron density for both peptides was very
well defined over the entire peptide length (Figure 9C,D). The N-terminal and C-terminal amino
acid residues of the peptide provide the majority of H-bond and van der Waals contacts
Figure 7. Binding affinity of extended ligands and their respective binding cores. (A) Measured IC50 of extended peptides (black fill) and the respective
predicted binding core (white fill). Blue line denotes 500 nM; binding affinities below this are considered binders. (B, C) Mutation analysis of
FVLELEPEWTVK and YLSPIASPLLDGKSLR with non-permissive F’ pocket residues. Blue letters denote the mutated residue. All data shown are the
results of two independent experiments run in triplicate or duplicate. P-values shown are the result of an unpaired two-tailed t-test.
DOI: 10.7554/eLife.12556.013
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(Supplementary file 4). When attention was shifted to the F- pocket of HLA-A*02:01, with the
shorter peptide this pocket was closed by the side chains of Thr80 and Tyr84 with Lys146 of the
MHC I providing a lid or cover above the F pocket thereby burying the peptide’s C-terminal 11th res-
idue underneath (Figure 9A,E). However, for HLA-A*02:01 in complex with FVLELEPEWTVK, the
side chain of Tyr84 swung up and out by almost 90 degrees (Figure 9A,F), opening the binding
groove so that a peptide might protrude from the groove at its C-termini. At the same time, Thr80
adopted a different rotamer, further opening the MHC I pocket toward the end of the a1-helix.
Lastly, there was a subtle but noticeable increase in the main chain distance between the a 1 and
a2-helices at the F’ pocket (Figure 9G). Together, these structural changes opened the F’ pocket
and allowed Lys12 of the peptide to protrude from the pocket.
We compared our structures to a previously reported structure of HLA-A*02:01 in complex with a
peptide that also extends its C-terminus from the F’ pocket (Collins et al., 1994). While the authors
anticipated the structural changes necessary to allow a peptide to protrude from the F’ pocket, the
reported structure shows a minor structural change where Tyr84, the key player in opening the F’
pocket, rotates slightly but does not swing out, and Thr80 did not change its rotamer. A slight
movement of the Lys146 side chain, which appeared to be sufficient to allow the small C-terminal
glycine to stick up, was reported (Figure 9G). However, in this previously reported model, amino
acids other than glycine could not extend from the F’ pocket due to steric clashes with the MHC I.
Here, we have identified a previously unreported mechanism that allows pathogen-encoded C-termi-
nally extended peptides to protrude out the end of the MHC I binding grove at the F’ pocket. The
Figure 8. Thermal denaturation of extended ligands. (A) Raw fluorescence of the melt curve for indicated peptide/
HLA-A*02:01 complex. (B) First derivative of the melt curve from thermal denaturation experiment for HLA-A*02:01
indicated peptide ligand. The melting temperature for each peptide was calculated from the minima of these
curves and is shown in the figure legend.
DOI: 10.7554/eLife.12556.014
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binding cores of these C-terminally extended peptides interacts with MHC I using the same peptide
register of canonical MHC I binders.
Discussion
Proteins secreted by T. gondii have been demonstrated to be an important source of immunogenic
MHC I peptide ligands (Grover et al., 2014). Indeed, the secreted dense granule proteins are the
best-characterized source of peptides for presentation by MHC I, and our study confirms these pro-
teins provide a number of MHC I ligands (Blanchard et al., 2008; Cardona et al., 2015;
Cong et al., 2011). However, many of the ligands we observe originate from non-secreted proteins,
including parasite cytoplasmic proteins. Enrichment in these proteins is unexpected given that most
T. gondii cytoplasmic proteins are not secreted and their cellular location should sequester them
Figure 9. Structural details of extended ligand binding to HLA-A*02:01. Binding of core peptide FVLELEPEWTV (A, C, E) and extended ligand
FVLELEPEWTVK (B, D, F) to HLA-A*02:01. Peptides are shown as sticks, while HLA-A*02:01 is shown as a molecular surface with electrostatic potential
contoured from -30kT/E to +30kT/E (positive charge in blue, negative in red). Peptide FVLELEPEWTV in green, and FVLELEPEWTVK in yellow. 2FoFc
electron density is shown as a blue mesh around the peptide (2 A˚ radius) FVLELEPEWTV (C) and FVLELEPEWTVK (D) and contoured at 1s Details of
peptide binding to the F’ pocket of MHC (E, F). MHCI residues that form H-bond interactions (blue dashed lines) with the peptide are labeled. MHC
residues that are critical for the F’ pocket formation are shown with electron density with same settings as in C and D. (F) Note how Thr80 (T80) and
Tyr84 (Y84) change position upon binding of extended ligand FVLELEPEWTVK. Those structural changes are not seen in PDB ID 2CLR (orange) when
superimposed with UFP (16–26) and UFP (16–27).
DOI: 10.7554/eLife.12556.015
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from the MHC I peptide processing machinery. Further, we identified many hypothetical proteins
sampled by MHC I. Proteomic data had previously been reported for all but one of these hypotheti-
cal proteins, and our data substantiates that these proteins are expressed by the tachyzoites within
the infected host (Gajria et al., 2008; Treeck et al., 2011; Xia et al., 2008). Additionally, a little less
than half (10/22) of the hypothetical proteins contain a predicted secretion signal sequence. These
data represent a substantial contribution to understanding patterns of T. gondii gene/protein
expression and demonstrate that secreted as well as non-secreted tachyzoite-expressed proteins are
accessible to host antigen presentation processes.
A previous study of MHC I and T. gondii indicated that ligands derived from the C-termini of T.
gondii source proteins are immunodominant (Feliu et al., 2013), and it was suggested that a proteo-
lytic insufficiency within infected murine cells meant that only peptides derived from the C-termini of
T. gondii source proteins would provide ligands of optimal length (Feliu et al., 2013). Consistent
with this, we found a dramatic C-terminal bias in the T. gondii derived ligands. However, it was
completely unexpected that host-derived ligands in the infected cell would also display a C-terminal
bias. Gene ontology annotation analysis indicated no bias in the cellular location of the source pro-
teins for these C-terminal ligands (data not shown), so it does not appear to be a protein’s location
within the cell that results in a C-terminal processing bias. How T. gondii is mediating this intracellu-
lar alteration in antigen processing and presentation is therefore an unsettled question, and it will be
interesting to see if protein ligand sampling is also biased in the closely related parasite Plasmodium
falciparum.
One of the most striking observations in this study is that infection leads to the MHC I presenta-
tion of T. gondii ligands that are longer than baseline host ligands. Most ligands of considerable
length are thought to be anchored to the B’ and F’ pockets of the MHC I groove via the peptide’s
P2 and PW side chains, respectively. In such models the long peptide ligands exhibit a central bulge
in order for the MHC I groove to accommodate the length of the extra residues (Hassan et al.,
2015; Tynan et al., 2005). Consistent with this model, several long T. gondii ligands identified fol-
low this P2/PW-anchor means of binding to MHC I. Rather unexpectedly, a group of long ligands did
not follow this model but instead were predicted to bind via a canonical N-terminal binding core
preceding the aforementioned C-terminal extension. A review of published ligand elution data con-
firms that C-terminally extended peptides are presented by membrane-bound HLA-A*02:01
(Hassan et al., 2015; Chen et al., 1994; Scull et al., 2012), yet the considerable number of
extended ligands observed in this in vitro model of T. gondii antigen processing and presentation
merits future confirmation in vivo. That notwithstanding, structural support for the binding of
extended peptide ligands in HLA-A*02:01 can also be found (Collins et al., 1994). In this example
the nonamer binding core of a calreticulin peptide is extended by a single C-terminal amino acid
that fits within the MHC I groove, yet this model was not consistent with T. gondii ligands that had
as many as 30 C-terminally appended amino acids. In order to resolve this enigma, an HLA-A*02:01
crystal was solved with FVLELEPEWTVK and with a version of this ligand minus the C-terminal K. This
led to the unprecedented observation that the C-terminal lysine at P12 displaced the Tyr84 residue
at the end of the HLA-A*02:01 binding groove. As such, Tyr84 emerged as a “swinging gate”
whereby a longer T. gondii peptide extended straight out the end of the HLA molecule at its C-ter-
minus when Tyr84 assumed an alternate up and out position – the open gate. With the shorter pep-
tide the Tyr84 was positioned down and in, assuming the traditional closed-groove orientation. A
Tyr84 in the open position is consistent with several extended T. gondii ligands and a number of
host ligands. This structural configuration is distinct from c-terminal extensions previously reported
with C-terminal extension of covalently linked peptides (Mitaksov et al., 2007) and predicted con-
figurations (Ho¨rig et al., 1999) where the peptide travels up and over Tyr84. Note that Tyr84 mod-
estly rotated to facilitate the reported binding of calretulin to HLA-A*02:01 (Collins et al., 1994),
and the gate-open displacement of Tyr84 observed here confirms that the MHC I binding pocket is
less rigid than previously realized. Importantly, this method of binding appears to be a major mecha-
nism by which T. gondii and peptides are bound and presented in contrast to host-derived peptides
where this mode of binding significantly less frequent.
The increased frequency of extended peptides following infection suggests that T. gondii ligands
emerge from a distinct pathway of antigen processing and presentation. Class I MHC peptide
ligands are typically derived from the proteasomal degradation of cytosolic proteins, active transport
by TAP into the lumen of the ER, further proteolytic trimming in the ER, and chaperone mediated
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loading into class I MHC prior to egress to the plasma membrane. In the case of T. gondii, parasites
are contained within a fusion resistant parasitophorous vacuole (PV), making it necessary that alter-
native mechanisms contribute to T. gondii protein degradation, transport, and trimming prior to pre-
sentation. Current evidence shows that T. gondii proteins secreted into the PV can be
retrotransolcated via the endoplasmic reticulum associated degradation (ERAD) complex from lumen
of the PV to the host cytosol where they are routed to MHC I (Blanchard et al., 2008; Feliu et al.,
2013; Grover et al., 2014; Gubbels et al., 2005). This process of presenting canonical peptide
ligands from exogenous non-cytosolic proteins by class I MHC is referred to as cross-presentation
(Blanchard and Shastri, 2010; Grotzke and Cresswell, 2015). The extended T. gondii ligands
observed here do not seem to fit this model of cross-presentation as their C-terminal extensions
suggest a lack of interaction with proteolytic agents of the host cytosol and as many T. gondii
ligands are derived from proteins not secreted into the PV. Rather, infected cells seem to exhibit a
distinct means of cross-presentation, almost as though extended ligands move directly from the PV
or the pathogen itself to the host’s ER, forgoing exposure to carboxypeptidases found in the cytosol
that are otherwise absent from the lumen of the ER. Indeed evidence of a semi-permeable channel
between the PV and the ER might explain the presentation of extended peptides (Goldszmid et al.,
2009). However it is that ligands of unusual length reach class I MHC, future studies of T cell immu-
nogenicity to T. gondii, and possibly to other large intracellular pathogens, must factor the distinct
environment of the infected cell into the identification of immune epitopes.
In summary, this study reports how antigens encoded by the large intracellular pathogen T. gon-
dii are processed and presented by the host cell’s MHC I. Studies of peptides that are naturally proc-
essed and presented by the MHC I of mammalian cells have historically used healthy, or uninfected,
cells to provide the baseline understanding for how antigens are made available for immune recog-
nition. A foundation has emerged whereby peptide ligands of 9 amino acids are enveloped into an
MHC I binding groove such that the central portions of the peptide ligand are available for review
by adaptive immune receptors, and a legion of structural and functional data support this paradigm.
Here we see that thousands of peptide ligands harvested from the MHC I of infected cells also fit
this canonical antigen processing and presentation model, but in parallel we observe that alternate
and unanticipated mechanisms result from infection and play a role in making T. gondii available for
immune recognition. That long ligands can extend from their C-termini in a linear fashion out the
end of what was previously recognized as a closed MHC I groove was unexpected. Our findings raise
a plethora of important questions that must now be addressed, including whether other large intra-
vacuolar pathogens such as Plasmodium and Mycobacterium species mediate similar changes to
MHC I ligand presentation, how infection remodels host cell biology to facilitate the delivery of long
extended ligands to MHC I, and the impact that unconventional ligand presentation has on adaptive
immune responses to infected cells.
Materials and methods
Cell lines and T. gondii strains
THP-1 cells acquired from ATCC (ATCC# TIB-202) were cultured in RPMI supplemented with 10%
FBS. THP-1 cells were routinely authenticated by HLA typing using sequence based typing at the
HLA-A, B, C, and DRB1 loci from an American Society for Histocompatibility and Immunogenetics
(ASHI) accredited laboratory (ASHI#03-5-OK-07-1) (Lanteri et al., 2011). The reported HLA type of
the THP-1 cells are HLA-A*02, -B*15, -C*03, -DRB1*01, -DRB1*15 (Battle et al., 2013;
Tsuchiya et al., 1980). The observed HLA type of the THP-1 cells used in all experiments is HLA-
A*02:01, -B*15:11, C*03:03, DRB1*01:01, DRB1*15:01. THP-1 cells were transfected with a soluble
form of HLA-A*02:01 as previously described (McMurtrey et al., 2008). HLA in the supernatant was
measured using a sandwich ELISA using W6/32 as a capture mAb and anti-b2m antibody as a detec-
tor. HLA producing cells were subcloned and used for T. gondii infection. Toxoplasma gondii strain
RH expressing GFP was propagated on human foreskin fibroblasts cells acquired from ATCC
(ATCC# SCRC-1041) cultured in DMEM supplemented with 10% FBS, glutamine and penicillin/strep-
tomycin. Parasites were released from host cells by passage through a 27-gauge needle
(Wiley et al., 2010) All host cell lines and parasites were routinely tested for Mycoplasma
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contamination with either the MycoAlert Mycoplasma Detection Kit (Lonza, Basel, Switzerland) or
Venor GeM Mycoplasma Detection Kit (Sigma-Aldrich, St. Louis MO) and found to be negative..
HLA production and ligand purification
HLA from uninfected and infected cells were purified as previously described (McMurtrey et al.,
2008; Yaciuk et al., 2014). Briefly, THP-1 cells producing sHLA-A*02:01 were seeded into a hollow
fiber bioreactor. For T. gondii infection, cells were expanded to confluence and then infected on day
27 with 3.72 x 109 parasites. Bioreactor supernatant containing HLA was collected and pooled over
the course of the seven day infection. HLA was purified from both infected and uninfected cells
using antibody affinity chromatography with an anti-VLDL antibody. HLA was eluted in 0.2 M acetic
acid and further acidified to 10% acetic acid. Peptide ligands were dissociated from the alpha chain
by heating to 75˚C for 15 min. Alpha chain and b-2m were separated from the eluted peptides by
3kDa cutoff ultrafiltration.
Monitoring T. gondii bioreactor infection
THP-1 cells were infected with GFP-expressing parasites in the bioreactor and cells were periodically
sampled from the extra capillary space of the bioreactor. 1x106 cells were stained with 1 ug of the
pan-HLA class I specific antibody W6/32 labeled with Alexafluor 647 and incubated at room temper-
ature for 30 min to differentiate whole cells from cell debris and parasites. Cells were washed with
1% BSA in PBS three times and then fixed with 1% PFA for 15 min at room temperature. Cells and
free parasites were measured using a BD FACS Calibur flow cytometer.
Two-dimensional LCMS
HLA peptide ligands are were identified with a two-dimensional LCMS system as described
(Yaciuk et al., 2014). Briefly, peptide pools were fractionated using high pH off-line reverse phase
HPLC. Each fraction was dried, resuspended in 10% acetic acid, and placed into an Eksigent NanoLC
400 U-HPLC auto sampler system (Sciex). Approximately twenty percent of each fraction was
injected onto a nano-LC column and eluted with a linear acetonitrile water gradient at low pH
(Yaciuk et al., 2014). Eluate was ionized with a nanospray III ion source and analyzed with a 5600 Tri-
ple-TOF mass spectrometer (Sciex). Survey and fragment spectra for all fractions were analyzed
using PEAKS (Bioinformatics Solutions Inc) and were searched against NCBInr database using Homo
sapiens (ID: 9606) or Toxoplasma gondii (ID: 5811) taxonomy filters. For Homo sapiens searches a
1% FDR was applied and for Toxoplasma gondii a 2% FDR was used. All T. gondii unmodified pep-
tide sequences were confirmed with fragmentation of a synthetic peptide.
Source protein analysis
All source proteins derived from T. gondii were manually converted from NCBInr format to ToxoDB
(www.toxodb.org) format including official protein names and gene symbols. T. gondii source pro-
tein gene IDs were used as input for the Gene Ontology Enrichment tool (Gajria et al., 2008).
Enrichments were calculated using T. gondii strain GT1, and both annotated as well as predicted
terms were considered. Reported p-values are the Bonferronii adjusted p-value.
HLA-A*02:01 binding predictions
Predicted HLA-A*02:01 binding affinities were generated for all eluted peptides using NetMHCpan-
2.8 (Hoof et al., 2009). The percentage rank score was used for all analysis. The percentage rank
score indicates how strong a peptide’s predicted binding affinity is compared to a large pool of nat-
urally occurring peptides. A rank score of 10% indicates that a peptide is amongst the 10% strongest
binding random natural peptides for HLA-A*02:01. Peptides with predicted rank scores <=10%
were classified as binders, all other peptides were considered non-binders. All non-binders were
screened for potential nested HLA-A*02:01 binders by predicting the binding affinity of all overlap-
ping 8–11mers within the eluted peptide sequence. A more conservative rank score <=2% was used
to identify nested binders. If multiple nested binders were identified within the same eluted peptide,
the nested binder with the strongest predicted binding affinity was selected. Permuted peptides
were generated by scrambling the amino acid sequence of the eluted peptide and predictions were
preformed in the same manner.
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Binding assay
Assays to quantitatively measure peptide binding to HLA-A*0201 (MHC I) molecules are performed
essentially as detailed elsewhere (Sidney et al., 2001; 2008; Sidney, 2013). In brief, 0.1–1 nM of
radiolabeled peptide is co-incubated at room temperature with 1 mM to 1 nM of purified HLA-
A*02:01 in the presence of a cocktail of protease inhibitors and 1 mM b2-microglobulin. Following a
two day incubation, HLA-A*02:01 bound radioactivity is determined by capturing the HLA/peptide
complexes on W6/32 (anti-class I) antibody coated Lumitrac 600 plates (Greiner Bio-one, Frickenhau-
sen, Germany), and measuring bound cpm using the TopCount (Packard Instrument Co., Meriden,
CT) microscintillation counter. Under the conditions utilized, where [label]<[HLA] and IC50  [HLA],
the measured IC50 values are reasonable approximations of the true Kd values (Cheng and Prusoff,
1973; Gulukota et al., 1997). Each competitor peptide is tested at six concentrations covering a
100000-fold dose range in three or more independent experiments. As a positive control, the unla-
beled version of the radiolabeled probe is tested in each experiment.
HLA-A*02:01 expression and purification for crystal structure
HLA-A*02:01 class I heavy chain ectodomain (residues 1–274) and human b-2 microglobulin (hb2m,
1–99) were expressed as inclusions bodies and refolded as reported previously (Garboczi et al.,
1994) with modifications as reported. Briefly, 15 mg of HLA-A heavy chain mixed with 3 mg of pep-
tide (GenScript) was then added to the refolding mix and further stirred at 4˚C for 72 hr. Final heavy
chain:light chain:peptide ratios were 2.5:1:12 for peptides FVLELEPEWTVK and FVLELEPEWTV. Fol-
lowing refolding, refolding mixture was spun at 50000g to remove any precipitated protein, super-
natant concentrated to about 3 ml and loaded onto a Superdex S200 HR16/60 gel filtration column.
Fractions containing refolded HLA-A*02:01-peptide complexes were pooled, concentrated to about
10–12 mg/mL and used for crystallization experiments.
Thermal denaturation assay
HLA-A*02:01-peptide complexes with peptides FVLELEPEWTV, FVLELEPEWTVK, YLSPIASPL and YL-
SPIASPLLDGKSLR were analyzed for thermal denaturation by differential scanning fluorimetry. HLA-
A*02:01-peptide complexes at 100 mM in reaction buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl)
were used as protein stock solution. Each reaction comprised of 1–2 ml protein stock solution, 2 ml of
SYPRO Orange dye (100X, Invitrogen) made up to 20 ml in reaction buffer. The experiment was per-
formed in triplicates for individual peptide complexes using a LightCycler 480 (Roche) in a 96-well
plate format. A temperature gradient from 20˚C - 85˚C at steps of 0.06˚C/sec and 10 acquisitions/˚C
was run. The melt curve of the total fluorescence was plotted against the temperature. The first
derivative of the melt curve was obtained from raw fluorescence data (temperature differential of
absolute fluorescence versus temperature) and plotted as well. The minima in the first derivative of
each melt curve, corresponding to the inflection point of the original melt curve, provided the met-
ing temperature (Tm) of each protein (Figure 8B) (Walden et al., 2014).
Crystallization and data collection
Thin plate-like crystals were obtained for HLA-A*02:01 complex with UFP (16–26) in 30% PEG 5000
MME, 0.1 M Tris-HCl pH 8.0, 0.2 M lithium sulfate and HLA-A*02:01 complex with UFP (16–27) in
30% PEG 4000, 0.1 M Tris-HCl pH 8.0, 0.2 M lithium sulfate. Crystals were obtained by sitting drop
vapor diffusion by mixing 0.15 ml protein and 0.15 ml of precipitant at 20˚C after 2–4 days. The crys-
tals were flash frozen in cryoprotectant (Reservoir solution: 100% glycerol - 3:1) using liquid nitrogen.
Diffraction data for HLA-A2/ UFP (16–26) and HLA-A2/ UFP (16–27) were collected remotely at
beamline 7.1 at the Stanford Synchrotron Radiation Light source (SSRL) and processed to 1.8 A˚ and
1.5 A˚ resolution, respectively using HKL2000 (Otwinowski and Minor, 1997). Phases were obtained
using the protein coordinates for HLA-A2 (PDB ID 3MRE) using molecular replacement with Phaser
MR (Storoni et al., 2004) in ccp4i (CCP4, 1994; Potterton et al., 2003) and provided unambiguous
electron density for both the peptides. Model building was carried out using COOT (Emsley and
Cowtan, 2004; Emsley et al., 2010). Structures were refined using Refmac (Deckert-Schlu¨ter et al.,
1994) to a final Rwork/Rfree of 0.164/0.222 for HLA-A2/UFP ( 16–26) (PDB ID 5D9S) and Rwork/Rfree of
0.195/0.219 for HLA-A2/UFP (16–27) (PDB ID 5DDH).
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